Literature DB >> 16873279

Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.

Moraima Guadalupe1, Sumathi Sankaran, Michael D George, Elizabeth Reay, David Verhoeven, Barbara L Shacklett, Jason Flamm, Jacob Wegelin, Thomas Prindiville, Satya Dandekar.   

Abstract

Although the gut-associated lymphoid tissue (GALT) is an important early site for human immunodeficiency virus (HIV) replication and severe CD4+ T-cell depletion, our understanding is limited about the restoration of the gut mucosal immune system during highly active antiretroviral therapy (HAART). We evaluated the kinetics of viral suppression, CD4+ T-cell restoration, gene expression, and HIV-specific CD8+ T-cell responses in longitudinal gastrointestinal biopsy and peripheral blood samples from patients initiating HAART during primary HIV infection (PHI) or chronic HIV infection (CHI) using flow cytometry, real-time PCR, and DNA microarray analysis. Viral suppression was more effective in GALT of PHI patients than CHI patients during HAART. Mucosal CD4+ T-cell restoration was delayed compared to peripheral blood and independent of the time of HAART initiation. Immunophenotypic analysis showed that repopulating mucosal CD4+ T cells were predominantly of a memory phenotype and expressed CD11 alpha, alpha(E)beta 7, CCR5, and CXCR4. Incomplete suppression of viral replication in GALT during HAART correlated with increased HIV-specific CD8+ T-cell responses. DNA microarray analysis revealed that genes involved in inflammation and cell activation were up regulated in patients who did not replenish mucosal CD4+ T cells efficiently, while expression of genes involved in growth and repair was increased in patients with efficient mucosal CD4+ T-cell restoration. Our findings suggest that the discordance in CD4+ T-cell restoration between GALT and peripheral blood during therapy can be attributed to the incomplete viral suppression and increased immune activation and inflammation that may prevent restoration of CD4+ T cells and the gut microenvironment.

Entities:  

Mesh:

Year:  2006        PMID: 16873279      PMCID: PMC1563811          DOI: 10.1128/JVI.00120-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Current strategies in the treatment of HIV infection.

Authors:  O J Cohen; A S Fauci
Journal:  Adv Intern Med       Date:  2001

2.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

3.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.

Authors:  A Oxenius; D A Price; P J Easterbrook; C A O'Callaghan; A D Kelleher; J A Whelan; G Sontag; A K Sewell; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

4.  Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.

Authors:  Brinda Emu; Elizabeth Sinclair; David Favre; Walter J Moretto; Priscilla Hsue; Rebecca Hoh; Jeffrey N Martin; Douglas F Nixon; Joseph M McCune; Steven G Deeks
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa.

Authors:  G Meng; M T Sellers; M Mosteller-Barnum; T S Rogers; G M Shaw; P D Smith
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

Review 6.  Biological parameters of HIV-1 infection in primary intestinal lymphocytes and macrophages.

Authors:  P D Smith; G Meng; M T Sellers; T S Rogers; G M Shaw
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

7.  Immune restoration with antiretroviral therapies: implications for clinical management.

Authors:  M M Lederman; H Valdez
Journal:  JAMA       Date:  2000-07-12       Impact factor: 56.272

8.  The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children.

Authors:  H M Spiegel; R Chandwani; M E Sheehy; J Dobroszycki; G Fennelly; A Wiznia; J Radding; M Rigaud; H Pollack; W Borkowsky; M Rosenberg; D F Nixon
Journal:  J Infect Dis       Date:  2000-06-27       Impact factor: 5.226

9.  Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection.

Authors:  U Malhotra; M M Berrey; Y Huang; J Markee; D J Brown; S Ap; L Musey; T Schacker; L Corey; M J McElrath
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

10.  Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Authors:  M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  127 in total

1.  Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy.

Authors:  Kenneth S Knox; Carol Vinton; Chadi A Hage; Lisa M Kohli; Homer L Twigg; Nichole R Klatt; Beth Zwickl; Jeffrey Waltz; Mitchell Goldman; Daniel C Douek; Jason M Brenchley
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

2.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

Review 3.  Pathogenesis of HIV in the gastrointestinal tract.

Authors:  Satya Dandekar
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

4.  An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.

Authors:  Brendan T Griffin; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2007-11-02       Impact factor: 4.200

Review 5.  Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections.

Authors:  Jacob D Estes
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

Review 6.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

7.  CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Authors:  M Vaccari; A Boasso; Z-M Ma; V Cecchinato; D Venzon; M N Doster; W P Tsai; G M Shearer; D Fuchs; B K Felber; G N Pavlakis; C J Miller; G Franchini
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

8.  HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Authors:  Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata
Journal:  Clin Infect Dis       Date:  2014-02-12       Impact factor: 9.079

9.  Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.

Authors:  Joseph C Mudd; Jason M Brenchley
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

Review 10.  Cardiovascular Disease, Statins, and HIV.

Authors:  Allison Ross Eckard; Eric G Meissner; Inderjit Singh; Grace A McComsey
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.